Zoetis Inc (ZTS)
176.71
+1.04
(+0.59%)
USD |
NYSE |
Nov 21, 16:00
176.71
0.00 (0.00%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 79.73B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -0.15% |
| Valuation | |
| PE Ratio | 33.22 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.826 |
| Price to Book Value | 15.23 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.432 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.256 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 46.52% |
Profile
| Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. |
| URL | https://www.zoetis.com |
| Investor Relations URL | https://investor.zoetis.com |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Nov. 04, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 31, 2024 |
Ratings
Profile
| Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. |
| URL | https://www.zoetis.com |
| Investor Relations URL | https://investor.zoetis.com |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Nov. 04, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 31, 2024 |